| Identification | Back Directory | [Name]
Benzyl (S)-1-((3-BroMo-4,5-Dihydroisoxazol-5-Yl)MethylaMino)-3-(4-Hydroxyphenyl)-1-Oxopropan-2-YlcarbaMate | [CAS]
744198-19-4 | [Synonyms]
KCC009
KCC-009
KCC 009
MRULUIQNANUWTK-ZVAWYAOSSA-N
Benzyl (S)-1-((3-BroMo-4,5-Dihydroisoxazol-5-Yl)MethylaMino)-3-(4-Hydroxyphenyl)-1-Oxopropan-2-YlcarbaMate
Carbamic acid, N-[(1S)-2-[[(3-bromo-4,5-dihydro-5-isoxazolyl)methyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]-, phenylmethyl ester | [Molecular Formula]
C21H22BrN3O5 | [MDL Number]
MFCD12032123 | [MOL File]
744198-19-4.mol | [Molecular Weight]
476.32 |
| Chemical Properties | Back Directory | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 250 mg/mL (524.86 mM; Need ultrasonic) | [form ]
Solid | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Biological Activity]
KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2].
The inhibition rates were 15.33±1.46 (%) for H1299/WT-p53 cells, and 14.31±1.90 (%) for H1299/M175H-p53 cells when cells were treated with KCC009 at concentration of 3.91 uM[1]. | [References]
[1]. Sheng Huaying, et al. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells. Med Sci Monit. 2016 Dec 21;22:5041-5048. [2]. L Yuan, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
http://m.is0513.com/ShowSupplierProductsList927327/0.htm |
|